Metaclipse Therapeutics is a preclinical stage biotech company developing novel cancer therapies that are tailored to each patient and their specific tumor. The Company’s first ‘personalized’ cancer therapy is for triple negative metastatic breast cancer. Metaclipse intends to commercialize its products through licensing agreements with major pharmaceutical companies after establishing their safety and effectiveness in early clinical trials by year-end 2019.